Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Danaher; Affymetrix; Trovagene; and More

NEW YORK (GenomeWeb) — Danaher announced this week that its board has approved a regular quarterly dividend of $.16 per share. The dividend will be payable on Apr. 29 to shareholders of record on Mar. 24.

Affymetrix said this week that French breeding-chicken producer Groupe Grimaud has selected Affy's Axiom genotyping platform for its genomic selection and poultry breeding program. Affy will develop multiple custom chicken genotyping microarrays in 96- and 384-array formats for the Axiom 384HT platform, and said that both its commercially available and custom-designed genotyping arrays for poultry will enable Grimaud to select chickens for desired traits and help identify candidates from pure-bred lines to move forward into production. Grimaud is also using Affy's rabbit genotyping array.

Trovagene announced this week that it entered into an agreement with Fortified Provider Network to cover Trovagene's Precision Cancer Monitoring services as an in-network participating laboratory provider for the members of Fortified's network. Separately, the company also said this week that it has signed a similar agreement with Three Rivers Provider Network.

Bruker announced this week that its board has approved the initiation of a dividend policy under which the company will aim to pay its stockholders a yearly dividend of $.16 per share, payable in equal quarterly installments. The board also declared an initial quarterly cash dividend of $.04 per share, payable on Mar. 24 to stockholders of record as of the close of business on Mar. 4.

KeyGene and the University of Minnesota announced this week that they have signed a licensing agreement to allow the university to use KeyGene's proprietary Sequence-Based Genotyping technology. The University of Minnesota Genomics Center said it plans to use the technology to aid in the research of plant breeding.

This week, Swiss proteomics company Biognosys announced that it will open its new North American office in Greater Boston in the second quarter of this year. The office will be the firm's first North American location. Biognosys plans to use funds raised in a Series C financing round to establish business development and service operations in the US, and to develop new workflows and products for high-content protein analysis.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.